Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
Completed · Phase 2
Conditions studied: Meningitis, Meningococcemia
In brief
This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02. Primary Objective: To evaluate the antibody responses to a booster dose of a tetravalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) in participants who had previously received Menactra® or Menomune® as adolescents in the MTA02 Study and antibody responses to a dose of Menactra® in naive adolescents.
Key facts
- Study ID
- NCT00777790
- Run by
- Sanofi Pasteur, a Sanofi Company
- People needed
- 241
- Starts
- 2004-02-01
- Expected to finish
- 2005-04-01
- Last updated by the study team
- 2014-02-14
Who can join
Age: 13 and older, up to 21. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 13 years of age but not yet 22 years of age at time of enrollment.
- For the Menactra® and Menomune® groups, participant received one dose of Menactra® or Menomune® in MTA02 trial and completed trial (2 blood samples, contacted for Month 6 safety follow up).
- For the Control group, participant has no previous history of any meningococcal vaccination.
- If < 18 years of age, participant has signed Institutional Review Board (IRB) approved informed assent form and his/her parent/legal guardian has signed an IRB-approved informed consent form.
- If ≥ 18 years of age, participant has signed an IRB-approved informed consent form.
- Able to provide vaccination log.
You may not qualify if…
- Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc).
- Known or suspected impairment of immunologic function.
- Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 100.4ºF (≥ 38.0ºC) at the time of inclusion.
- For the Menactra® and Menomune® groups, history of documented invasive meningococcal disease or previous meningococcal vaccination with the exception of meningococcal vaccination given as part of MTA02 trial.
- For the Control group, history of documented invasive meningococcal disease or previous meningococcal vaccination.
- Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn.
- Received any vaccine in the 14-day period prior to study vaccination, or scheduled to receive any vaccination during the 14-day period after study vaccination.
- Suspected or known hypersensitivity to any of the vaccine components.
- Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
- In females, a positive or equivocal urine pregnancy test at the time of vaccination.
- Enrolled in another clinical trial.
- Any condition, which, in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the vaccine.
Where it is running
- Study site — Atlanta, Georgia, United States
- Study site — Marietta, Georgia, United States
- Study site — Woburn, Massachusetts, United States
- Study site — Albany, New York, United States
- Study site — Akron, Ohio, United States
- Study site — Columbus, Ohio, United States
- Study site — Sellersville, Pennsylvania, United States
- Study site — Kingsport, Tennessee, United States
- Study site — Norfolk, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.